[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444075":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AYA cancer patients",null,"Patients aged 18-39 years, with a first histological and\u002For cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.",[13],"Procedure: Blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Blood sampling","Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).",[9],[21],{"name":22,"affiliation":5,"role":23},"J. Nuver, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+31 50 361 2821","j.nuver@umcg.nl",[30],{"facility":5,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Groningen","9713 GZ","Netherlands","NL",{"type":37,"coordinates":38},"Point",[39,40],6.56667,53.21917,{"lat":40,"lon":39},[43,44],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48],{"name":49,"class":50},"UMCG Kanker Researchfonds","UNKNOWN","100444075","early-ageing-during-therapy-in-aya-cancer-patients-100444075",false,"NCT05062707","Early Ageing During Therapy in AYA Cancer Patients","Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients","Inclusion Criteria:\n\n* Aged 18-39 years at cancer diagnosis\n* Having a histologically and\u002For cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.\n* Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.\n\nExclusion Criteria:\n\n* patients who are not able to understand the patient information letter and informed consent form\n* patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis\n* patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).","ALL","18 Years","39 Years",{"count":62,"type":63},120,"ESTIMATED","OBSERVATIONAL","Longitudinal cohort study; measurements before start of systemic therapy and one year later.",[67,68,69,70,71,72,73,74],"Cancer","Leukemia","Hodgkin Lymphoma","Testicular Cancer","Osteosarcoma","Ewing Sarcoma","Breast Cancer","Cervical Cancer","2025-05-12",{"date":77,"type":78},"2025-05-13","ACTUAL",{"date":80,"type":78},"2022-02-10",{"date":82,"type":63},"2025-07",{"name":5,"class":6},1]